Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Current Assets (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Current Assets over the past 15 years, most recently at $85.7 million for Q2 2025.

  • For Q2 2025, Current Assets rose 5.73% year-over-year to $85.7 million; the TTM value through May 2025 reached $85.7 million, up 5.73%, while the annual FY2025 figure was $85.7 million, 5.73% up from the prior year.
  • Current Assets for Q2 2025 was $85.7 million at Lifecore Biomedical, Inc. \De\, up from $84.2 million in the prior quarter.
  • Over five years, Current Assets peaked at $158.3 million in Q1 2021 and troughed at $74.2 million in Q3 2024.
  • A 5-year average of $104.7 million and a median of $89.8 million in 2023 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: plummeted 35.58% in 2023 and later increased 10.58% in 2025.
  • Year by year, Current Assets stood at $150.6 million in 2021, then decreased by 20.9% to $119.1 million in 2022, then plummeted by 35.58% to $76.7 million in 2023, then rose by 6.71% to $81.9 million in 2024, then rose by 4.67% to $85.7 million in 2025.
  • Business Quant data shows Current Assets for LFCR at $85.7 million in Q2 2025, $84.2 million in Q1 2025, and $81.9 million in Q4 2024.